Accolade, Inc. (NASDAQ:ACCD) Shares Bought by Northern Trust Corp

Northern Trust Corp raised its holdings in Accolade, Inc. (NASDAQ:ACCD) by 4.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 637,012 shares of the company’s stock after purchasing an additional 27,127 shares during the quarter. Northern Trust Corp owned about 0.78% of Accolade worth $2,179,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of ACCD. Nisa Investment Advisors LLC increased its stake in shares of Accolade by 15,113.1% during the fourth quarter. Nisa Investment Advisors LLC now owns 55,680 shares of the company’s stock worth $190,000 after acquiring an additional 55,314 shares during the period. Raymond James Financial Inc. purchased a new position in Accolade during the fourth quarter worth about $120,000. Savant Capital LLC raised its holdings in Accolade by 182.1% during the fourth quarter. Savant Capital LLC now owns 52,794 shares of the company’s stock worth $181,000 after purchasing an additional 34,082 shares in the last quarter. Rhumbline Advisers raised its holdings in Accolade by 1.7% during the fourth quarter. Rhumbline Advisers now owns 115,136 shares of the company’s stock worth $394,000 after purchasing an additional 1,967 shares in the last quarter. Finally, Blair William & Co. IL raised its holdings in Accolade by 54.0% during the fourth quarter. Blair William & Co. IL now owns 81,763 shares of the company’s stock worth $280,000 after purchasing an additional 28,673 shares in the last quarter. 84.99% of the stock is currently owned by institutional investors and hedge funds.

Accolade Stock Performance

Shares of Accolade stock opened at $7.02 on Monday. Accolade, Inc. has a 12-month low of $3.08 and a 12-month high of $7.70. The company has a current ratio of 2.63, a quick ratio of 2.63 and a debt-to-equity ratio of 0.67. The stock has a market cap of $575.59 million, a PE ratio of -3.12 and a beta of 2.10. The company has a 50-day moving average of $7.01 and a two-hundred day moving average of $5.94.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on ACCD shares. Stephens reissued an “equal weight” rating and set a $7.03 price target on shares of Accolade in a report on Wednesday, February 12th. Piper Sandler cut shares of Accolade from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 5th. Thirteen investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $6.51.

Accolade Company Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.